The Mumbai-based Maneesh Pharmaceutical Company is expanding its product portfolio by adding around 15-18 new products to its product basket with an estimated investment of around Rs 50 crore. All these new products will be launched in the next financial year. Presently, all products are at trial stage.
Svizera Health Remedies, a division of Maneesh Pharmaceutical, has launched its new calcium chewable tablets 'Shaktikal' for children and young mothers. A pack of Shaktikal costs Rs 74 and contains 60 tablets. Shaktikal is set to take on the highly competitive market in India.
Talking to Pharmabiz, Gauri Sapte, director business development, Maneesh Pharmaceutical said, "We have a well designed future plan for the next fiscal. We are investing around Rs 50 crore for the new product development. But as of now the new products schedule will take another six months. To part finance this, we are doing internal accruals. The company has made impressive achievements in the last year. For the next financial year, we have strong product pipeline. We will be launching our all-new products in a phase wise manner".
Commenting on launch of new product she said, "Calcium is an essential constituent of good health and is vital for building and maintaining strong bones and teeth. It is required all through life, but especially in the informative years of childhood and for women of all ages and in cases of osteoporosis. The company believes in pioneering woman's needs. We specially focus on gynaecology and infertility and offer solution right from menarche to menopause".
Avra Ghosh, general manager marketing and sales, Svizera Health Remedies, said, "Shaktikal is an exceptional attempt by us to breakthrough in the calcium oral solid market, which is around Rs 225 crore. Shaktikal hopes to create awareness of the necessity of calcium in our diet and a niche for itself in the Indian market.
The company's foray into FMCG and OTC products, coupled with intensive research and development in TB drug formulation, has put in al league of its own internationally. It is the pioneer for the SCC-4, a four drug fixed dose combination in granular form, which is available in a single dose sachet. Its last financial fiscals annual turnover was Rs 525 crore. The company exports its products under the Svizera brand to over 70 countries, except Australia and New Zealand. But company enjoys good business with Brazil and Latin America. "We are increasing our brand portfolio in the international market as well as we are also expanding our business unit in the domestic market. We are also looking forward in the CRAMs segment", she further added.